CorMedix (CRMD) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evolus (EOLS) has outperformed CorMedix (CRMD) over the past year, losing 4.8% versus a loss of 45.6%. Over five years, EOLS leads with a +14.4% price change compared with +3.9% for CRMD. Evolus is the larger company by market cap ($431.5 million vs $419.2 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs +11.6%).
On valuation, CorMedix trades at a lower forward P/E (15.1x vs 22.7x for Evolus). CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -17.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | EOLS |
|---|---|---|
| Share price | $5.27 | $6.52 |
| Market cap | $419.16M | $431.55M |
| 1-day change | +3.74% | -6.86% |
| YTD return | -54.69% | -1.95% |
| 1-year return | -45.56% | -4.82% |
| 5-year return | +3.94% | +14.39% |
| P/E ratio (TTM) | 8.23 | — |
| Forward P/E | 15.06 | 22.68 |
| EPS (TTM) | $0.64 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $297.18M |
| Revenue growth (YoY) | +617.03% | +11.61% |
| Net income (latest FY) | $163.06M | $-51.64M |
| Gross margin | 88.46% | 66.33% |
| Operating margin | 48.17% | -10.99% |
| Net margin | 52.31% | -17.38% |
| 52-week high | $13.02 | $9.31 |
| 52-week low | $4.47 | $3.86 |
| Distance from 52-week high | -59.52% | -29.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +161.86% | +136.20% |
| Average volume | 1.44M | 925.77K |
| Shares outstanding | 79.54M | 66.19M |
| Employees | 191 | 365 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed CRMD by 40.7 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -17.4 cents for Evolus.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs +11.61%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
CRMD vs EOLS FAQ
Which is bigger, CorMedix or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $419.16M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or EOLS?
EOLS returned -4.82% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.